

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
July 25, 2007

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **July 25, 2007**

**Keryx Biopharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-30929**  
(Commission File Number)

**13-4087132**  
(IRS Employer Identification No.)

**750 Lexington Avenue**  
**New York, New York 10022**  
(Address of Principal Executive Offices)

**(212) 531-5965**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act.
  - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - £ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
- 
-

**Item 2.02. Results of Operations and Financial Condition.**

On July 25, 2007, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing results of operations for the second quarter ended June 30, 2007, and announced that it would host a conference call on July 26, 2007, for investors where Keryx will discuss its results of operations and financial results. A copy of the press release is being furnished as Exhibit 99.1 to this report.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: July 25, 2007

By: /s/ Beth F. Levine

---

Beth F. Levine  
General Counsel and Chief Compliance Officer

---

**INDEX TO EXHIBITS**

**Exhibit  
Number Description**

99.1 Press Release dated July 25, 2007.

---